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ABSTRACT 
Background and Aims: Despite the high prevalence of substance use among people in the 
US criminal justice system, little is known about the incidence of overdose mortality by use 
patterns, drug convictions, and supervision setting. We examined the associations between 
these characteristics and overdose mortality.   
Design: Retrospective cohort study. 
Setting and participants: Individuals sentenced to prison, jail, probation, or jail and 
probation for a felony conviction in Michigan, USA from 2003 to 2006. 
Measurements: Using the National Death Index, we assessed overdose mortality through 
December 2012. We calculated overdose mortality rates by pre-sentence opioid use, drug 
convictions, and supervision setting. Multivariable analyses were conducted using competing 
risks regression with time-varying covariates.  
Findings: Among 140,266 individuals followed over a mean of 7.84 years (SD = 1.52), 
14.9% of the 1,131 deaths were due to overdose (102.8 per 100,000 person-years [PY]). Over 
the follow-up, more than half of overdose deaths occurred in the community (57.7%), nearly 
a third (28.8%) on probation, and 12.8% on parole. The adjusted risk of overdose death was 
lower on probation (hazard ratio [HR] = 0.71, 95% CI = 0.60, 0.85) than in the community 
without probation or parole (HR = 1.00) but not significantly different on parole (HR = 1.13, 
95% CI = 0.87, 1.47). Pre-sentence daily opioid use (HR = 3.54, 95% CI = 3.24, 3.87) was 
associated with an increased risk. Drug possession (HR = 1.11, 95% CI = 0.93, 1.31) and 
delivery convictions (HR = 0.92, 95% CI = 0.77, 1.09) were not significantly associated with 
overdose mortality.  
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Conclusions: Based on the absolute or relative risk, parole, probation, and community 
settings are appropriate settings for enhanced overdose prevention interventions. Ensuring 
that individuals with pre-sentence opioid use have access to harm reduction and drug 
treatment services may help to prevent overdose among people involved with the criminal 
justice system.   
 
INTRODUCTION 
Amidst epidemic increases in overdose rates in the United States, (1) correctional, addiction 
treatment, public health, and harm reduction agencies have increasingly been working to 
prevent overdose deaths by providing naloxone and medications for opioid use disorder to 
people involved in the criminal justice system. (2-9) These efforts have been driven by the 
substantial proportions of people involved in the criminal justice system due to drug offenses, 
(10, 11) the high prevalence of criminal justice contact among people who use heroin and 
other opioids, (12) and the scale of the system, which supervised 6.6 million people at year-
end 2016. (13) For example, in U.S. jails, which largely detain individuals prior to sentencing 
or for short sentences, and prisons, which are state or federal facilities that generally 
incarcerate people serving sentences of more than a year, approximately one quarter of 
individuals report past heroin or other opiate use. (14) In the month after release from prison, 
when individuals are commonly on parole, the fatal overdose risk is heightened. (15-20) 
Probation settings, which supervised more than 3.7 million people at year-end 2016, are also 
important because drug offenses are the most serious offenses for nearly a quarter of people 
on probation, (10) and approximately 6% report past month heroin or other opioid use. (21)     
Despite efforts to prevent fatal overdose among people with criminal justice involvement, 
remarkably little is known about the individual-level drug use characteristics, conviction 
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types, and supervision settings associated with highest overdose risks. For example, fatal 
overdose rates on probation and the independent association of drug possession and delivery 
convictions with overdose fatalities have not been quantified. In criminal justice settings, data 
availability is limited compared with traditional health care settings and public health 
agencies. Formal opioid use disorder diagnoses, comprehensive overdose histories, and 
biological markers may not be systematically collected and routine overdose surveillance is 
not conducted in probation and parole settings. (22) Additionally, medical and behavioral 
health records may be difficult to access, particularly if health services are contracted to 
external providers. Nonetheless, commonly available administrative data include basic drug 
use histories collected during pre-sentence investigations, conviction type, and supervision 
setting over time. Further, data can be linked to state and national vital records to ascertain 
deaths from overdose.  
Measuring overdose rates across criminal justice populations and settings may help inform 
the design, delivery and evaluation of preventive interventions. Different criminal justice 
settings present distinct barriers to deliver medications for opioid use disorder and harm 
reduction services to those most likely to benefit. (23, 24) Prisons, for example, may have 
limited access to medications for opioid use disorder and naloxone to treat opioid overdoses 
and there are few evidence-based guidelines on how to prioritize treatment provision or 
naloxone distribution. (6, 25, 26) On probation and parole, competing needs, financial 
constraints, and coordination challenges may limit access to community-based services. (27-
29)  
We used data from a state criminal justice system linked with the National Death Index to 
assess the association between pre-sentence substance use patterns, drug conviction, and 
overdose mortality. We also evaluated overdose mortality rates in prison, parole, and 
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probation, and among people with prior convictions but living in the community without 
probation or parole.  
METHODS 
Study Design and Setting 
We conducted a retrospective longitudinal cohort study using data from the Michigan 
Department of Corrections (MDOC), which has jurisdiction over prisons, felony probation, 
and parole and conducts the pre-sentence investigations for all individuals convicted of a 
felony regardless of what setting they are sentenced to. In Michigan, all adults and juveniles 
sentenced as adults who are convicted of offenses for which the statutory maximum is more 
than one year of incarceration can be sentenced to the MDOC’s prisons. Individuals 
sentenced to less than one year of incarceration are sentenced to jail.  
Study Cohort 
The study population included individuals 15 and older with new felony sentences in 
Michigan from January 1, 2003 to December 31, 2006 (N=144,271). Juveniles under 18 and 
sentenced as children were not included because they were sentenced in the juvenile system, 
but juveniles sentenced as adults (n=1,785; 1.3%) were included because they were exposed 
to similar conditions and programming to adults in the MDOC. The focal sentence was the 
first conviction that led to entry into the cohort. In Michigan, at the time of this study, 
individuals convicted of a felony offense may have be sentenced to prison, probation, jail, jail 
plus probation, or other sentences (fines or community service). Individuals sentenced to 
prison were first held in a prison reception and guidance center for intake. Jail sentences were 
typically 12 months or less; such individuals were housed in county jails. We included those 
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initially sentenced to jail (7.7% of the study population) and those sentenced to a combination 
of jail and probation (38.6%).  
 
We did not include short-term jail stays due to probation violations or pre-trial detention. We 
excluded non-discretionary and identifiable specialty sentences which offered special family 
or drug services but were too rare to analyze separately, including life sentences (n=2436, 
1.7%) and specialty courts (n=1659, 1.1%). The final cohort included 140,266 individuals, 
including individuals sentenced to jail (n=10,788), probation (n=50,202), jail followed by 
probation (n=54,093), prison (n=24,516), and other sentences such as fines or community 
service (n=656) during the four-year baseline period. Follow-up was censored at the time of 
death or December 31, 2012, whichever came first.  
Exposures 
Our primary exposures of interest were criminal justice system setting, pre-sentence opioid 
use, and a felony conviction for drug possession or delivery recorded in the MDOC 
administrative databases. These databases derive from the pre-sentence investigation and 
include demographics, body mass index, substance use history, mental health treatment 
history, and prior criminal record. A field agent typically prepared the pre-sentence 
investigation report using a process described in an MDOC policy directive. (30) Criminal 
justice setting indicated whether the individual was in prison, on probation, on parole, or in 
the community not on probation or parole at each day of follow-up, and the cumulative 
number of admissions and number of months in each setting. Time in the community may 
have included subsequent jail stays, but these are typically brief (mean of 26 days per stay in 
2017 (31) ).   
Pre-sentence investigation reports provided self-reported use of alcohol, any opioids, 
marijuana, nonmedical stimulants, or other drugs at any time before conviction, including 
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never, daily, weekly, and occasional (i.e., any use monthly and less) use frequency. We 
hypothesized that there would be a positive and dose-dependent association between the 
frequency of opioid use and overdose, with most opioid overdoses occurring among 
individuals who reported daily opioid use. These hypotheses were not pre-registered and 
results should be considered exploratory.  
Drug convictions for any substance were based on offense descriptions. (32) Because drug 
possession convictions may reflect the extent of substance use, we hypothesized that 
individuals with drug possession convictions would be at higher overdose risk than 
individuals with drug delivery convictions, and that both would be more strongly associated 
with overdose than no drug convictions. Data also included the date and county of conviction, 
total offense severity score, (33) whether the felony conviction was the person’s first, number 
of prior arrests (0 to 4, 5 to 9, and 10+), and time in prison prior to sentencing.  
MDOC administrative databases were also the source for other characteristics known to be 
associated with overdose or all-cause mortality among individuals released from prison. (15, 
34) These potential confounders or precision variables included age, sex, race (white vs. 
nonwhite), marital status (single vs. ever married), education, and pre-sentence employment. 
Study Outcomes  
We linked identifiers from the MDOC administrative databases to the National Death Index 
(NDI)-Plus, (35) a computerized database of deaths abstracted from death certificates in all 
50 states and Puerto Rico. (36) For matches to known decedents, NDI-Plus provided the date, 
state, and cause of death. International Classification of Disease (ICD) -10 codes were used to 
classify overdose deaths from any substance(s) and the subset of opioid overdose deaths. (15)  
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To compare death rates between cohort members and the general Michigan population, we 
used the Centers for Disease Control and Prevention’s Wide-ranging OnLine Data for 
Epidemiologic Research (CDC WONDER) (37) for death counts, population, and causes of 
death for Michigan residents. Deaths and person-years of cohort members who died in 
Michigan were deducted from total state deaths reported in CDC WONDER.  
Statistical Analysis 
For each exposure of interest (criminal justice setting, opioid use, and drug conviction), we 
first calculated crude mortality rates (CMR) as the number of deaths per 100,000 person-
years of follow-up with 95% confidence intervals (CI) by exposure status. Person-years were 
calculated by summing exposure time. Incidence rate ratios (IRR) and 95% CIs were 
calculated comparing CMRs by exposure status. We also examined crude overdose death 
rates in the month after prison, parole, and probation release. We used indirect 
standardization to calculate expected deaths in the study cohort based on death rates from the 
standard population of Michigan residents (i.e., of similar age, gender and race distribution). 
We present standardized mortality ratios (SMRs), the ratio of observed to expected deaths in 
the study cohort.  (38) 
Competing-risks regression models were used to examine the independent associations of all 
three exposures of interest with time-to-death from overdose. Our primary outcome of 
interest was overdose deaths. However, individuals may have died from other causes which 
would preclude the primary outcome from occurring. To account for such competing events, 
we employed competing risks regression to estimate subdistribution hazard ratios. (39) 
Standard errors were clustered by county. Opioid overdose mortality was assessed separately 
as a post-hoc analysis using a competing risks model. Models were also adjusted for sex, 
race, marital status, education, mental health treatment history and body mass index. Age, 
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criminal justice setting, and admissions to and months in prison, on probation, or on parole 
since sentencing were treated as time-varying covariates. Sentence length was correlated with 
sentence type and therefore not included in the models. With the exception of education, all 
independent variables had less than 1.2% missingness and the overall number of cells with 
missing values was 0.3%. Education, however, was missing for 14.8% of the sample, thus we 
used multiple imputation by chained equations to generate five datasets with imputed values 
for analysis. (40) 
In post-hoc analyses, we explored excluding the first month post-release, a time known to be 
associated with a high risk of death, from IRRs comparing death rates by setting.  
RESULTS 
Cohort Characteristics 
The cohort (N=140,266) was 82.9% male and had a mean age of 31.8 (standard deviation 
[SD] 11.1, range 15 to 94; Table 1). At baseline, 6.9% of the cohort members reported daily 
opioid use, with another 2.0% and 2.6% reporting weekly or occasional opioid use, 
respectively. Among individuals who reported daily opioid use, 74.9% also used alcohol, 
70.6% also used marijuana, and 65.5% also used stimulants. Opioid use was more common 
among those who were sentenced to prison (8.3%) or jail (8.8%) than jail plus probation 
(7.4%) or probation alone (5.4%). In the cohort, 13.8% were sentenced for a drug possession 
conviction and 15.3% were sentenced for a drug delivery conviction. Most (82.6%) drug 
possession convictions and 40.3% of drug delivery convictions were for narcotics/cocaine, 
which include the United States Drug Enforcement Administration Schedule I and II 
substances, including opioids such as heroin, oxycodone, and fentanyl. 
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Overdose  
Over a mean follow-up of 7.84 years (SD=1.52), there were 7611 deaths, of which 14.9% 
(n=1131) were overdoses (Table 2). One hundred and eleven (9.8%) overdose deaths 
occurred outside of Michigan.  More than half of overdose deaths (56.1%, n=634) involved at 
least one opioid, including natural and semi-synthetic opioids (n=144), heroin (n=333), 
methadone (n=135), and/or synthetic opioids other than methadone (n=91). Sixty percent 
(n=383) opioid overdoses also involved another substance, such as cocaine (21%), 
benzodiazepines (14%) or alcohol (12%) The mean age at overdose death was 39.2 years 
(SD=10.5).  
Overdose mortality rates were 102.8 per 100,000 person-years (95% CI=97.0, 109.0; Table 
3). The overdose mortality rate was 7.0 times (95% CI=6.6, 7.4) that among state residents. 
Between 2003 and 2012, the crude overdose death rate for Michigan was 10.8 per 100,000. 
After subtracting the overdose deaths in our study population from the state numbers, the rate 
was 9.4 per 100,000. The opioid overdose mortality rate was 57.6 per 100,000 person-years 
(95% CI=53.3, 62.3; Table S1).  
Over half (57.7%) of the overdose deaths occurred in the community while not on probation 
or parole, 28.8% occurred on probation, and 12.8% occurred on parole (Table 3). Fewer than 
10 overdoses occurred in prison. Compared with being in the community not on probation or 
parole, overdose rates were highest on parole (incidence rate ratio [IRR]=1.64, 95% CI=1.36, 
1.97) and lower on probation (IRR=0.81, 95% CI=0.71, 0.93) and in prison. In the first 
month after prison release, there were 11 overdose deaths (25.6% of deaths in the first month) 
and the overdose mortality rate was 259.0 per 100,000 person-years (95% CI=143.4, 467.6). 
Even after excluding the first month after release (Table S2), the incidence rate ratios were 
similar (parole vs. community: IRR=1.65, 95% CI=1.36, 1.99; probation vs. community: 
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IRR=0.82, 95% CI=0.71, 0.93). In the first month after probation or parole ended, the 
overdose mortality rates were 194.0 per 100,000 person-years (95% CI=114.9, 326.7) and 
119.2 per 100,000 person-years (95% CI=29.8, 476.6), respectively. The first month after 
probation ended was associated with a significantly higher overdose mortality rate than other 
periods on probation (IRR=1.96, 95% CI=1.06-3.34) but there was no significant association 
for first month after parole ended (IRR=0.60; 95% CI=0.07, 2.19) compared with other 
periods on parole. 
The mean sentence length was 153.3 days (SD 121.8; median=122 days, 25th to 75th IQR: 45 
to 243 days) for people sentenced to jail or jail and probation.  
Individuals who used daily opioids had a nearly six-fold higher crude overdose mortality 
rates (IRR=5.89, 95% CI=5.13, 6.75) than individuals who did not use opioids. Daily opioid 
use was associated with a significantly higher overdose mortality rate (414.2 per 100,000 
person-years, 95% CI=370.1, 463.5) than occasional use (268.4 per 100,000 person-years, 
95% CI=314.3, 336.0).  
Individuals with a drug possession conviction had a 1.86 times higher overdose mortality rate 
(95% CI=1.61, 2.15) than individuals without a drug conviction, but the rate was not higher 
among individuals with a drug delivery conviction (IRR=0.97, 95% CI=0.80, 1.16).  
Approximately 60% of overdose deaths occurred among individuals reporting no opioid use 
prior to their first sentence, and more than half of these (51.3%, n=353) were opioid-related. 
Thirty-nine percent (n=247) of those with an opioid overdose neither reported opioid use nor 
had a drug conviction.  
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The Association between Setting, Opioid Use and Drug Possession Conviction and Overdose 
Compared with being in the community not on parole or probation, being in prison or on 
probation were associated with reduced risks of overdose mortality in adjusted models 
(prison: hazard ratio [HR]=0.03, 95% CI=0.01, 0.07; probation: HR=0.71, 95% CI=0.60, 0.85 
), but not being on parole (HR=1.13, 95% CI=0.87, 1.47; Table 1). Cumulative probation 
months and number of probation admissions were significantly associated with overdose 
mortality. Individuals who reported daily, weekly, or occasional opioid use had elevated risks 
of overdose mortality relative to no use (daily HR=3.54, 95% CI=3.24, 3.87; weekly 
HR=2.99, 95% CI=2.24, 4.00; occasional HR=2.65, 95% CI=2.15,3.26). Daily other drug use 
(HR=1.42, 95% CI=1.03, 1.96) was associated with increased risks of overdose mortality, but 
marijuana (HR=0.81, 95% CI=0.69, 0.96 ) was protective and alcohol (HR=1.02, 95% 
CI=0.84, 1.24) and stimulant use (HR=0.94, 95% CI=0.76, 1.16) were not associated.  
In adjusted analyses, drug possession (HR=1.11, 95% CI=0.93, 1.31) and delivery 
convictions (HR=0.92, 95% CI=0.77, 1.09) were not associated with overdose mortality 
(Table 1). 
Post-hoc Analyses 
Daily opioid use was associated with a greater than 4-fold risk in opioid overdose (HR=4.17, 
95% CI=3.40, 5.12; Table S3).  
Among people without prior opioid use (Table S5), drug possession was not associated with 
overdose mortality (HR=1.01; 95% CI 0.81-1.27). Table S5 lists the leading causes of death 
among individuals with a drug possession conviction.  
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DISCUSSION  
In this criminal justice population, overdose accounted for nearly 15% of all deaths over 
almost 8 years of follow-up. Opioids were involved in more than half of overdose deaths, 
consistent with national and statewide trends. The highest overdose mortality rate occurred 
while people were on parole, but, over the entire follow-up, the highest proportion of 
overdoses occurred while people were no longer involved with parole or probation and were 
in the community. Transitional periods after prison and probation were high-risk. Daily 
opioid use identified during pre-sentencing investigations was associated with a greater than 
three-fold risk of overdose. Drug possession and delivery convictions were not significantly 
associated with overdose in adjusted models.  
Based on our findings, reducing barriers and enhancing access to medications for opioid use 
disorder and naloxone may be beneficial for individuals with prior opioid use in community, 
parole, and probation settings. Our findings also suggest that the transition from parole and 
probation to the community may be an important juncture for such interventions, perhaps 
because individuals lose access to ancillary services provided by parole or probation and are 
no longer monitored. More than a third of opioid overdose deaths were among individuals 
who did not have a history of opioid use prior to their sentence, suggesting that this indicators 
may not be adequately sensitive. Some individuals may not have reported opioid use during 
pre-sentence investigations whereas others likely initiated opioid use later. Thus, additional 
indicators will be needed to identify all those could benefit from prevention interventions. In 
New York City, one study targeted overdose education and naloxone to individuals visiting 
jails. (41) Further studies could identify additional indicators and develop and test formal 
overdose predictive models among criminal justice populations to help inform public health 
intervention targeting. Alternatively, universal, rather than targeted, approaches to screening 
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for substance use disorders and offering treatment and naloxone in parole and probation 
settings may be needed. Additional services, such as patient navigation,(42) may help reduce 
barriers to treatment and services during high-risk transitions.  
We identified significant differences in overdose mortality rates across criminal justice 
settings. The overdose mortality rate was low in prison, consistent with an “incapacitation 
effect” (43, 44) related to restricted access to prescribed and illicit opioids in prisons. 
Individuals are subject to monitoring in prison, and there may be opportunities to intervene 
before an overdose becomes fatal. While treatment for opioid use disorders in prisons and 
naloxone provision at release are associated with reduced mortality risks after release, (3, 45-
48) individuals in the United States frequently cannot access medications for opioid use 
disorder during incarceration. (6, 25, 49)  
Our findings highlight the high risk of overdose among criminal justice populations in 
community settings, including parole, probation, and after supervision has been completed.  
Some barriers are similar across parole and probation settings. Parole and probation offices 
generally do not have medical staff or pharmacy services and are not required to provide 
access to medications for opioid use disorder or naloxone to prevent opioid overdose deaths. 
Judges and parole and probation officers may not support the use of medications for opioid 
use disorder. A lack of insurance coverage can also be a barrier to treatment. (50) However, 
there may be differences in parole and probation that impact overdose risk. While people on 
parole and probation may experience social instability, individuals on parole may have more 
housing insecurity, lower social and family support, and fewer employment options than 
individuals on probation due to the challenges associated with reentry. (51) Further research 
could be used to identify differences in barriers to treatment and overdose prevention 
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between probation and parole settings and effective interventions to reduce the risks in each 
setting.  
This study was conducted in a single US state, which may not be generalizable to other states 
and countries. Based on the limitations of available criminal justice data, we did not have 
information about ethnicity, opioid use patterns, opioid use disorder diagnoses and treatment, 
severity of mental health disorder, receipt of prescriptions for opioids over time, urine 
toxicology, or stays in local jails after the initial sentence. (52) Given that treatment for 
opioid use disorder, including prison-based treatment, is known to be associated with 
reductions in mortality, (48) treatment availability might have influenced the mortality rates 
we observed. We may not have identified all overdose deaths, including deaths outside the 
United States, and some heroin and fentanyl overdoses may have been inaccurately 
categorized. (53-56) Since 2012, heroin and fentanyl overdose rates have increased, (1) not 
captured in our results. However, our study is one of the largest studies of overdose deaths in 
any longitudinally observed denominated population; this allowed us to examine subgroups 
not previously examined and adjust for more potential confounders. Information on risk and 
protective factors in this cohort should be used to generate hypotheses for future general 
population overdose studies.  
Based on the absolute or relative risk, parole, probation, and community settings are 
appropriate settings for enhanced overdose prevention interventions. Ensuring that 
individuals with pre-sentence opioid use have access to harm reduction and drug treatment 
services may help to prevent overdose among people involved with the criminal justice 
system.   
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 Table 1. Characteristics of individuals sentenced for a felony conviction in Michigan and the unadjusted and multivariable association 
between characteristics and overdose mortality. 
 
 No. (%) Unadjusted HR (95% CI) Adjusted
a HR (95% CI) 
Sex    
Male 116,314 (82.9) 1.00 1.00 
Female 23,952 (17.1) 1.37 (1.19-1.58) 1.02 (0.88-1.19) 
Race    
White 81,483 (58.1) 1.00 1.00 
Non-White 58,783 (41.9) 0.26 (0.23-0.31) 0.28 (0.22-0.36) 
Pre-Sentence Employment  - 0.76 (0.64-0.91) 0.57 (0.45-0.73) 
Mental health treatment history 26,830 (19.1) 2.30 (2.03-2.60) 1.65 (1.37-1.98) 
Alcohol use    
Never 45,670 (32.6) 1.00 1.00 
Occasional 46,162 (32.9) 1.07 (0.92-1.25) 0.79 (0.67-0.94) 
Weekly 31,428 (22.4) 1.32 (1.12-1.55) 0.87 (0.75-1.00) 
Daily 17,006 (12.1) 1.80 (1.51-2.15) 1.02 (0.84-1.24) 
Marijuana use    
Never 53,468 (38.1) 1.00 1.00 
Occasional 34,525 (24.6) 1.16 (1.00-1.35) 0.95 (0.84-1.07) 
Weekly 23,813 (17.0) 1.25 (1.05-1.46) 1.07 (0.87-1.31) 
Daily 28,460 (20.3) 1.06 (0.90-1.25) 0.81 (0.69-0.96) 
Opioid use     
Never 124,125 (88.5) 1.00 1.00 
Occasional 3,673 (2.6) 3.82 (3.01-4.84) 2.65 (2.15-3.26) 
Weekly 2,741 (2.0) 4.38 (3.39-5.66) 2.99 (2.24-4.00) 
Daily 9,727 (6.9) 5.90 (5.16-6.76) 3.54 (3.24-3.87) 
Stimulant use     
Never 94,700 (67.5) 1.00 1.00 
Occasional 18,907 (13.5) 2.27 (1.95-2.63) 1.22 (1.03-1.43) 
Weekly 13,099 (9.3) 2.19 (1.84-2.60) 1.10 (0.92-1.32) 
Daily 13,560 (9.7) 2.03 (1.71-2.42) 0.94 (0.76-1.16) 
Other drug use    
Never 105,363 (75.1) 1.00 1.00 
Occasional 30,552 (21.8) 0.83 (0.71-0.97) 0.96 (0.80-1.14) 
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Weekly 2,186 (1.6) 1.75 (1.22-2.51) 0.86 (0.68-1.09) 
Daily 2,165 (1.5) 2.76 (2.06-3.69) 1.42 (1.03-1.96) 
Number of prior arrests    
0-4 66,406 (47.3) 1.00 1.00 
    5-9 40,797 (29.1) 1.62 (1.40-1.88) 1.43 (1.23-1.66) 
10+ 33,063 (23.6) 2.44 (2.12-2.81) 1.84 (1.48-2.28) 
Drug possession conviction    
No 120,902 (86.2) 1.00 1.00 
Yes 19,364 (13.8) 1.85 (1.61-2.13) 1.11 (0.93-1.31) 
Drug delivery conviction    
No 118,842 (84.7) 1.00 1.00 
Yes 21,424 (15.3) 0.86 (0.72-1.02) 0.92 (0.77-1.09) 
Setting    
   In the community not on parole or probation - 1.00 1.00 
   In prison - 0.04 (0.02-0.08) 0.03 (0.01-0.07) 
   On parole - 1.65 (1.38-1.98) 1.13 (0.87-1.47) 
   On probation - 0.84 (0.72-0.98) 0.71 (0.60-0.85) 
Cumulative prison months    
0 - 1.00 1.00 
   1-48 - 0.90 (0.78-1.04) 0.94 (0.75-1.18) 
   49+  - 0.31 (0.20-0.49) 0.97 (0.57-1.65) 
Prison admissions, number - 0.91 (0.81-1.01) 1.27 (1.00-1.61) 
Cumulative probation months - 1.00 (1.00b-1.00) 1.01 (1.00-1.01) 
Probation admissions, number - 1.20 (1.06-1.37) 1.45 (1.29-1.63) 
Cumulative parole months - 1.02 (1.01-1.02) 1.01 (1.00b-1.02) 
Parole admissions, number - 1.46 (1.32-1.61) 0.93 (0.64-1.36) 
HR=hazard ratio 
aModel adjusted for age (time-varying), marital status, education, body mass index, months in prison prior to sentence, offense severity score, offense severity 
score squared, first time felony offense, and initial sentence type  
b<1.00 before rounding
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Table 2. Deaths among cohort members followed through December 2012. 
Cause of Death (ICD-10 code[s]) 
Deaths  
No. (%)a 
All causes 7611 (100) 
Overdose (X40-49) 1131 (14.9) 
Opioid-related (T40.1, T40.2, T40.3, T40.4)  634 (56.1) 
Heroin (T40.1)  333 (52.5) 
Natural and semi-synthetic opioids (T40.2)  144 (12.7) 
Methadone (T40.3)  135 (21.3) 
Synthetic opioids other than methadone (T40.4) 91 (8.1) 
Cocaine (T40.5)  230 (20.3) 
Alcohol (T51.0-T51.9)  141 (12.5) 
Benzodiazepines (T42.4) 106 (9.4) 
Antidepressants (T43.0, T43.1, T43.2)   30 (2.7) 
Psychostimulants (T43.6)   17 (1.5) 
Neuroleptics (T43.3, T43.4, T43.5)   17 (1.5)  
Toxic gases (T58, T59.0-T59.9)  12 (1.1) 
Unspecified drugs, medicaments, or substances (T50.9) 478 (42.3)  
Other and unspecified narcotics (T40.6) and cannabis (T40.7) 54 (4.8)  
Other drugs, medicaments, and substances (T39.0-T39.9, T42.0-T42.3, 
T42.5-T42.9, T44.0-T44.9, T45.0-T45.9) and other psychotropics (T43.8, 
T43.9) 
36 (3.2)  
aNot mutually exclusive, as deaths can involve more than one substance 
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Table 3. Overdose mortality rates (deaths per 100,000 person-years) among cohort 
members (N=140,266) followed through 2012 and comparisons in overdose mortality 
rates by pre-sentence opioid use, drug conviction, and setting. 
 
Overdose 
Deaths 
No. (%)  
Crude Overdose 
Mortality Rate (95% 
CI) IRR (95% CI) 
Full cohort 1131 102.8 (97.0-109.0) 
 
Setting 
   
  In the community not on 
probation/parole 653 (57.7) 121.7 (112.7-131.4) (Reference) 
  In prison <10 a - - 
  On parole 145 (12.8) 199.9 (169.9-235.2) 1.64 (1.36-1.97) 
  On probation 326 (28.8) 98.9 (88.7-110.2) 0.81 (0.71-0.93) 
Opioid use 
   
  Never 688 (60.8)  70.4 (65.3-75.8) (Reference) 
  Occasional 76 (6.7) 268.4 (214.3-336.0) 3.81 (2.97-4.84) 
  Weekly 64 (5.7) 307.4 (240.6-392.8) 4.37 (3.33-5.65) 
  Daily 303 (26.8) 414.2 (370.1-463.5) 5.89 (5.13-6.75) 
Drug convictionb 
   
  None 732 (64.7) 92.5 (86.0-99.4) (Reference) 
  Drug possession 257 (22.7) 171.8 (152.1-194.2) 1.86 (1.61-2.15) 
  Drug delivery 142 (12.6) 89.4 (75.8-105.4) 0.97 (0.80-1.16) 
Initial sentencec    
  Jail only 129 (11.4) 153.7 (129.4-182.7) (Reference) 
  Jail with probation 475 (42.0) 112.0 (102.4-122.6) 
0.73 (0.60-
0.89) 
  Prison 150 (13.3) 76.6 (65.3-90.0) 
0.50 (0.39-
0.64) 
  Probation 374 (33.1) 95.5 (86.3-105.7) 
0.62 (0.51-
0.76) 
IRR=incidence rate ratio 
aSuppressed due to low counts cell (<10) 
bIf both a drug possession and drug delivery conviction, classified as drug possession 
cOther sentences suppressed due to low counts cell (<10) 
  
